Jaroslaw P Maciejewski

List of Publications by Year
in descending order

323	11,479	50276	31849
papers	citations	46 h-index	101 g-index

328	328	328	11977
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. American Journal of Clinical Pathology, 2022, 157, 586-594.	0.7	1
2	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	1.3	3
3	Tâ€cell large granular lymphocytic leukemia associated with inclusion body myositis. International Journal of Laboratory Hematology, 2022, 44, 27-28.	1.3	2
4	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Advances, 2022, 6, 100-107.	5.2	12
5	Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. IScience, 2022, 25, 103679.	4.1	6
6	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	15
7	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. Seminars in Hematology, 2022, 59, 47-53.	3.4	3
8	Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia, 2022, 36, 601-612.	7.2	11
9	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. Hematological Oncology, 2022, , .	1.7	3
10	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nature Communications, 2022, 13, 1038.	12.8	13
11	Sulfur Amino Acid Supplementation Abrogates Protective Effects of Caloric Restriction for Enhancing Bone Marrow Regrowth Following Ionizing Radiation. Nutrients, 2022, 14, 1529.	4.1	1
12	Aplastic anemia: Quo vadis?. Seminars in Hematology, 2022, 59, 54-55.	3.4	3
13	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nature Communications, 2022, 13, 1981.	12.8	23
14	Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia, 2022, 36, 2086-2096.	7.2	2
15	Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discovery, 2022, 3, 410-427.	5.0	7
16	Complex landscape of alternative splicing in myeloid neoplasms. Leukemia, 2021, 35, 1108-1120.	7.2	39
17	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia, 2021, 35, 1023-1036.	7.2	62
18	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells, Molecules, and Diseases, 2021, 87, 102528.	1.4	8

#	Article	IF	Citations
19	Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines. Leukemia and Lymphoma, 2021, 62, 473-477.	1.3	0
20	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leukemia and Lymphoma, 2021, 62, 735-738.	1.3	5
21	Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. Leukemia, 2021, 35, 1176-1187.	7.2	4
22	Novel invariant features of Good syndrome. Leukemia, 2021, 35, 1792-1796.	7.2	11
23	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kitâ€“positive Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 113-118.	0.4	4
24	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. Leukemia, 2021, 35, 3324-3328.	7.2	2
25	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood, 2021, 137, 3685-3689.	1.4	50
26	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia, 2021, 35, 1365-1379.	7.2	41
27	How I manage acquired pure red cell aplasia in adults. Blood, 2021, 137, 2001-2009.	1.4	29
28	Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. Cell Reports, 2021, 35, 108989.	6.4	23
29	Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers, 2021, 13, 2649.	3.7	12
30	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood, 2021, 138, 1885-1895.	1.4	32
31	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight, 2021, 6, .	5.0	12
32	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood, 2021, 138, 1928-1938.	1.4	45
33	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2021, 27, 917.e1-917.e9.	1.2	3
34	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 3737-3746.	1.6	90
35	Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell, 2021, 28, 1966-1981.e6.	11.1	49
36	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Advances, 2021, 5, 4361-4369.	5.2	9

#	Article	IF	Citations
37	Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. Cancers, 2021, 13, 4418.	3.7	11
38	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. Blood Cells, Molecules, and Diseases, 2021, 91, 102595.	1.4	2
39	TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. Seminars in Hematology, 2021, 58, 27-34.	3.4	9
40	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia, 2021, 35, 2431-2434.	7.2	10
41	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood, 2021, 138, 2781-2798.	1.4	27
42	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 602-602.	1.4	1
43	Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage. Blood, 2021, 138, 1148-1148.	1.4	3
44	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. Blood, 2021, 138, 3666-3666.	1.4	1
45	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. Blood, 2021, 138, 610-610.	1.4	2
46	A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia. Blood, 2021, 138, 786-786.	1.4	0
47	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer Journal, 2021, 11, 187.	6.2	11
48	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 4303-4303.	1.4	0
49	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia, 2021, , .	7.2	1
50	Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia. Blood, 2021, 138, 375-375.	1.4	2
51	A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2021, 138, 1249-1249.	1.4	2
52	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 603-603.	1.4	1
53	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. Blood, 2021, 138, 3486-3486.	1.4	2
54	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. Blood, 2021, 138, 1093-1093.	1.4	0

#	Article	IF	Citations
55	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. Blood, 2021, 138, 4467-4467.	1.4	1
56	Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies. Blood, 2021, 138, 3985-3985.	1.4	1
57	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia, 2020, 34, 957-962.	7.2	32
58	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. Leukemia, 2020, 34, 327-330.	7.2	3
59	Genomics of therapy-related myeloid neoplasms. Haematologica, 2020, 105, e98-e101.	3.5	23
60	Rare germline variant contributions to myeloid malignancy susceptibility. Leukemia, 2020, 34, 1675-1678.	7.2	8
61	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. Leukemia and Lymphoma, 2020, 61, 1242-1245.	1.3	1
62	Extended experience with a nonâ€cytotoxic DNMT1â€targeting regimen of decitabine to treat myeloid malignancies. British Journal of Haematology, 2020, 188, 924-929.	2.5	15
63	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood, 2020, 136, 2249-2262.	1.4	59
64	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Communications Biology, 2020, 3, 493.	4.4	30
65	Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Annals of Hematology, 2020, 99, 1505-1514.	1.8	63
66	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	1.4	28
67	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
68	5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. Haematologica, 2020, 105, e213-e215.	3.5	2
69	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.	2.5	4
70	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood, 2020, 136, 1851-1862.	1.4	112
71	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers, 2020, 12, 357.	3.7	11
72	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. British Journal of Haematology, 2020, 189, 318-322.	2.5	10

#	Article	IF	Citations
73	Distinctive and common features of moderate aplastic anaemia. British Journal of Haematology, 2020, 189, 967-975.	2.5	10
74	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Research, 2020, 80, 2031-2044.	0.9	36
75	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. Blood, 2020, 136, 33-35.	1.4	2
76	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. Blood, 2020, 136, 8-8.	1.4	1
77	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. Blood, 2020, 136, 31-32.	1.4	1
78	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. Blood, 2020, 136, 2-2.	1.4	1
79	Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms. Blood, 2020, 136, 38-40.	1.4	7
80	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. Blood, 2020, 136, 32-33.	1.4	2
81	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. Blood, 2020, 136, 1-1.	1.4	1
82	A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase. Blood, 2020, 136, 32-33.	1.4	0
83	Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 8-8.	1.4	0
84	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. Blood, 2020, 136, 25-25.	1.4	0
85	Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). Blood, 2020, 136, 54-55.	1.4	0
86	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. Blood, 2020, 136, 21-22.	1.4	0
87	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 2-3.	1.4	0
88	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. Blood, 2020, 136, 28-28.	1.4	0
89	Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations. Blood, 2020, 136, 7-8.	1.4	1
90	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. Blood, 2020, 136, 28-28.	1.4	1

#	Article	IF	Citations
91	Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive. Blood, 2020, 136, 26-27.	1.4	2
92	Molecular and Expression Characterization of Monosomy 7 and Del(7q). Blood, 2020, 136, 33-33.	1.4	0
93	Implication of Piga Genotype on Clinical Features of PNH. Blood, 2020, 136, 34-35.	1.4	0
94	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	1.4	3
95	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. Blood, 2020, 136, 34-35.	1.4	0
96	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. Blood, 2020, 136, 20-21.	1.4	0
97	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. Blood, 2020, 136, 2-3.	1.4	0
98	Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features. Blood, 2020, 136, 34-35.	1.4	1
99	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 13-14.	1.4	2
100	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	1.4	0
101	Role of Oligoadenylate Synthetases in Myeloid Neoplasia. Blood, 2020, 136, 29-30.	1.4	0
102	Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders. Blood, 2020, 136, 29-30.	1.4	1
103	TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity. Blood, 2020, 136, 2-3.	1.4	1
104	Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia. Blood, 2020, 136, 36-36.	1.4	0
105	The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia, 2019, 33, 2779-2794.	7.2	28
106	BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. Clinical Cancer Research, 2019, 25, 2513-2522.	7.0	11
107	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 2019, 33, 2842-2853.	7.2	43
108	Impact of germline CTC 1 alterations on telomere length in acquired bone marrow failure. British Journal of Haematology, 2019, 185, 935-939.	2.5	9

#	Article	IF	Citations
109	Chronic myeloid leukemia: Two mysteries. Leukemia Research, 2019, 79, 3-5.	0.8	3
110	Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Advances, 2019, 3, 339-349.	5.2	36
111	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	5.2	84
112	Subclonal STAT3 mutations solidify clonal dominance. Blood Advances, 2019, 3, 917-921.	5.2	28
113	Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Advances, 2019, 3, 2164-2178.	5.2	26
114	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	5.2	34
115	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nature Communications, 2019, 10, 5386.	12.8	53
116	Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia, 2019, 33, 612-624.	7.2	26
117	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2019, 54, 1281-1286.	2.4	24
118	New drugs for pharmacological extension of replicative life span in normal and progeroid cells. Npj Aging and Mechanisms of Disease, 2019, 5, 2.	4.5	8
119	BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leukemia and Lymphoma, 2019, 60, 1587-1590.	1.3	16
120	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. American Journal of Hematology, 2019, 94, E37-E41.	4.1	17
121	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. Blood, 2019, 134, 844-844.	1.4	3
122	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2696-2696.	1.4	1
123	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. Blood, 2019, 134, 4238-4238.	1.4	2
124	Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. Blood, 2019, 134, 842-842.	1.4	3
125	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. Blood, 2019, 134, 2091-2091.	1.4	11
126	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia. Blood, 2019, 134, 914-914.	1.4	1

#	Article	IF	Citations
127	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia. Blood, 2019, 134, 880-880.	1.4	3
128	Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2019, 2019, 97-104.	2.5	25
129	TET2 mutations and clonal dynamics. Oncotarget, 2019, 10, 2010-2011.	1.8	1
130	Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis. ELife, 2019, 8, .	6.0	14
131	T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.. Journal of Clinical Oncology, 2019, 37, e19072-e19072.	1.6	0
132	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). Blood, 2019, 134, 1281-1281.	1.4	0
133	The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases. Blood, 2019, 134, 769-769.	1.4	0
134	Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity. Blood, 2019, 134, 1279-1279.	1.4	1
135	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia. Blood, 2019, 134, 564-564.	1.4	0
136	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. Blood, 2019, 134, 5043-5043.	1.4	0
137	TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins. Blood, 2019, 134, 1200-1200.	1.4	0
138	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 1226-1226.	1.4	0
139	MPO as a Novel Susceptibility Gene in Myeloid Malignancies. Blood, 2019, 134, 5402-5402.	1.4	1
140	Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. Blood, 2019, 134, 1572-1572.	1.4	0
141	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. Blood, 2019, 134, 3743-3743.	1.4	0
142	Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI). Blood, 2019, 134, 2089-2089.	1.4	0
143	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. Blood, 2019, 134, 2595-2595.	1.4	1
144	Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets. Blood, 2019, 134, 1703-1703.	1.4	2

#	Article	IF	Citations
145	Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia. Blood, 2019, 134, 2553-2553.	1.4	2
146	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood, 2019, 134, 4271-4271.	1.4	0
147	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research, 2018, 24, 1705-1715.	7.0	80
148	Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene, 2018, 37, 1949-1960.	5.9	169
149	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer Journal, 2018, 8, 4.	6.2	43
150	Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia, 2018, 32, 2250-2262.	7.2	120
151	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leukemia and Lymphoma, 2018, 59, 416-422.	1.3	72
152	Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. British Journal of Haematology, 2018, 183, 133-136.	2.5	11
153	Rational management approach to pure red cell aplasia. Haematologica, 2018, 103, 221-230.	3.5	57
154	The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy. British Journal of Haematology, 2018, 182, 730-733.	2.5	11
155	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103.	1.4	40
156	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood, 2018, 132, 2309-2313.	1.4	38
157	Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia, 2018, 32, 1751-1761.	7.2	54
158	Transcriptomic rationale for synthetic lethalityâ€targeting <scp>ERCC</scp>1 and <scp>CDKN</scp>1A in chronic myelomonocytic leukaemia. British Journal of Haematology, 2018, 182, 373-383.	2.5	5
159	Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. Leukemia, 2018, 32, 2507-2511.	7.2	11
160	Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). Genomics, Proteomics and Bioinformatics, 2018, 16, 172-186.	6.9	22
161	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. Journal of Clinical Investigation, 2018, 128, 4260-4279.	8.2	97
162	Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. Oncotarget, 2018, 9, 2050-2057.	1.8	16

#	Article	IF	Citations
163	Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. Blood, 2018, 132, 3866-3866.	1.4	0
164	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. Blood, 2018, 132, 4352-4352.	1.4	1
165	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 2075-2075.	1.4	0
166	Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action. Blood, 2018, 132, 1302-1302.	1.4	0
167	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. Blood, 2018, 132, 3074-3074.	1.4	0
168	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. Blood, 2018, 132, 1527-1527.	1.4	0
169	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. Blood, 2018, 132, 371-371.	1.4	0
170	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 2017, 129, 2347-2358.	1.4	268
171	Molecular features of early onset adult myelodysplastic syndrome. Haematologica, 2017, 102, 1028-1034.	3.5	20
172	DDX41-related myeloid neoplasia. Seminars in Hematology, 2017, 54, 94-97.	3.4	49
173	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nature Communications, 2017, 8, 15102.	12.8	88
174	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 183-198.	7.4	32
175	Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology, 2017, 18, 236-245.	14.5	85
176	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	21.4	348
177	Origins of myelodysplastic syndromes after aplastic anemia. Blood, 2017, 130, 1953-1957.	1.4	50
178	Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. Hematology American Society of Hematology Education Program, 2017, 2017, 66-72.	2.5	13
179	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. Journal of Clinical Investigation, 2017, 127, 3527-3542.	8.2	35
180	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget, 2017, 8, 6483-6495.	1.8	34

#	Article	IF	Citations
181	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2017, 130, 779-779.	1.4	2
182	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. Blood, 2017, 130, 878-878.	1.4	0
183	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	4.1	18
184	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. American Journal of Hematology, 2016, 91, 406-409.	4.1	20
185	High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood, 2016, 128, 2465-2468.	1.4	86
186	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer, 2016, 16, 652.	2.6	12
187	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica, 2016, 101, e224-e227.	3.5	36
188	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. Blood, 2016, 128, 1505-1505.	1.4	1
189	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. Blood, 2016, 128, 1659-1659.	1.4	2
190	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. Blood, 2016, 128, 4301-4301.	1.4	2
191	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4336-4336.	1.4	8
192	The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed. Blood, 2016, 128, 444-444.	1.4	5
193	The Role of LUC7L2 in Splicing and MDS. Blood, 2016, 128, 5504-5504.	1.4	7
194	Myb expression is critical for myeloid leukemia development induced by Setbp1 activation. Oncotarget, 2016, 7, 86300-86312.	1.8	32
195	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. Blood, 2016, 128, 4293-4293.	1.4	0
196	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica, 2015, 100, e434-e437.	3.5	27
197	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	27.0	508
198	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	16.8	341

#	Article	IF	Citations
199	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3437-3439.	1.3	20
200	Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptorâ€“TRAF6 signaling. Journal of Experimental Medicine, 2015, 212, 1967-1985.	8.5	93
201	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	8.5	137
202	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. Journal of Biomedical Informatics, 2015, 58, 104-113.	4.3	9
203	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.9	127
204	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica, 2015, 100, 91-99.	3.5	88
205	Mutations in G protein Î² subunits promote transformation and kinase inhibitor resistance. Nature Medicine, 2015, 21, 71-75.	30.7	106
206	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. Blood, 2015, 126, 1645-1645.	1.4	1
207	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. Blood, 2015, 126, 1662-1662.	1.4	9
208	Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. Blood, 2015, 126, 2507-2507.	1.4	2
209	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
210	Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. PLoS ONE, 2015, 10, e0145394.	2.5	25
211	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. Journal of Clinical Oncology, 2015, 33, 11047-11047.	1.6	1
212	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. Blood, 2015, 126, 1350-1350.	1.4	1
213	Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia. Blood, 2015, 126, 2216-2216.	1.4	0
214	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	1.4	1
215	Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. Blood, 2015, 126, 2848-2848.	1.4	0
216	Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes. Blood, 2015, 126, 612-612.	1.4	28

#	Article	IF	Citations
217	Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). Blood, 2015, 126, 4491-4491.	1.4	0
218	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. Blood, 2015, 126, 611-611.	1.4	0
219	Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-Î°B Gene Network. Cell Reports, 2014, 8, 1328-1338.	6.4	64
220	Synergistic Effect of Major Histocompatibility Complex Class Iâ€“Related Chain A and Human Leukocyte Antigenâ€“DPB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1835-1840.	2.0	17
221	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 326-341.	7.4	118
222	ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood, 2014, 123, 3675-3677.	1.4	22
223	Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood, 2014, 124, 1790-1798.	1.4	204
224	Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. Journal of Clinical Investigation, 2014, 124, 4529-4538.	8.2	103
225	Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms. Blood, 2014, 124, 3581-3581.	1.4	0
226	Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. Blood, 2014, 124, 784-784.	1.4	0
227	Molecular pathogenesis of myelodysplastic syndromes. Translational Medicine @ UniSa, 2014, 8, 19-30.	0.5	11
228	Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood, 2013, 122, 4077-4085.	1.4	62
229	STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood, 2013, 122, 2453-2459.	1.4	128
230	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. SAGE Open Medical Case Reports, 2013, 1, 2050313X1349870.	0.3	3
231	Whole Exome Sequencing Detecting Kinesin Family Gene Defects In Myeloid Neoplasm. Blood, 2013, 122, 2762-2762.	1.4	0
232	Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies. Blood, 2013, 122, 2807-2807.	1.4	1
233	SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913.	27.0	681
234	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood, 2012, 120, 3048-3057.	1.4	360

#	Article	IF	Citations
235	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	1.4	2,458
236	Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes. Nature Precedings, 2012, , .	0.1	0
237	Introduction: Molecular Pathogenesis of Hematologic Malignancies. Seminars in Oncology, 2012, 39, 9-12.	2.2	4
238	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 1260-1260.	1.4	1
239	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. Blood, 2012, 120, 1696-1696.	1.4	3
240	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 1973-1973.	1.4	2
241	Whole Exome Analysis Reveals Spectrum of Gene Mutations in Juvenile Myelomonocytic Leukemia. Blood, 2012, 120, 170-170.	1.4	0
242	Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-Î²B. Blood, 2012, 120, 557-557.	1.4	0
243	SNP arrayâ€“based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood, 2011, 117, 6876-6884.	1.4	117
244	Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood, 2011, 118, 4384-4393.	1.4	63
245	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. Blood, 2011, 118, 400-400.	1.4	5
246	Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction. Blood, 2011, 118, 457-457.	1.4	2
247	Clinical and Genomic Characterization of Chromosome 7 Lesions in Myeloid Malignancies,. Blood, 2011, 118, 3549-3549.	1.4	4
248	Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions. Blood, 2011, 118, 2795-2795.	1.4	0
249	A Novel View of Paroxysmal Nocturnal Hemoglobinuria (PNH) Pathogenesis: Do Pathologic PNH Hematopoietic Stem/Progenitor Cells (HSPCs) Displace Normal HSPCs From Their Niches in Bone Marrow Because They Are More Motile Due to Defective Adhesion and Enhanced Migratory Properties?. Blood, 2011, 118, 732-732.	1.4	0
250	Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA). Blood, 2011, 118, 1726-1726.	1.4	0
251	Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes. Blood, 2011, 118, 2412-2412.	1.4	0
252	Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology. Blood, 2011, 118, 791-791.	1.4	0

#	Article	IF	Citations
253	Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. Blood, 2011, 118, 271-271.	1.4	9
254	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 2015-2015.	1.4	9
255	A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,. Blood, 2011, 118, 3830-3830.	1.4	0
256	Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML),. Blood, 2011, 118, 3566-3566.	1.4	0
257	Pathogenesis of MONOSOMY 7 In BONE MARROW FAILURE SYNDROMES. Blood, 2011, 118, 2411-2411.	1.4	1
258	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities,. Blood, 2011, 118, 4137-4137.	1.4	0
259	Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q). Blood, 2010, 116, 4016-4016.	1.4	6
260	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. Blood, 2010, 116, 3076-3076.	1.4	0
261	SNP-A Karyotyping Provides Clinically Relevant Results In Myeloid Hematologic Disorders with Unsuccessful Routine Cytogenetic Testing.. Blood, 2010, 116, 3374-3374.	1.4	0
262	HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases. Blood, 2010, 116, 1724-1724.	1.4	0
263	Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH). Blood, 2010, 116, 2001-2001.	1.4	0
264	CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders.. Blood, 2010, 116, 3396-3396.	1.4	2
265	A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression.. Blood, 2010, 116, 1687-1687.	1.4	0
266	Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia.. Blood, 2010, 116, 1171-1171.	1.4	0
267	Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygozity on Chromosome 7 In Myeloid Malignancies. Blood, 2010, 116, 297-297.	1.4	3
268	Gene Alterations In Acute Megakaryoblastic Leukemia (AMKL): a Comparison of AMKL with and without Down Syndrome. Blood, 2010, 116, 875-875.	1.4	0
269	Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica, 2009, 94, 1407-1414.	3.5	35
270	Application of arrayâ€based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. British Journal of Haematology, 2009, 146, 479-488.	2.5	131

#	Article	IF	Citations
271	A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).. Blood, 2009, 114, 3797-3797.	1.4	6
272	C-Cbl but Not TET2 Mutations Are Present in Patients with Juvenile Myelomonocytic Leukemia.. Blood, 2009, 114, 420-420.	1.4	1
273	Identification of Genetic Polymorphisms Contributing to Risk in MDS Using Innovative GWAS Approaches.. Blood, 2009, 114, 734-734.	1.4	0
274	Reconciling Phenotype with Genotype in the MPN: Impact of SNP Array-Based Chromosomal Analysis.. Blood, 2009, 114, 1893-1893.	1.4	4
275	Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood, 2008, 112, 965-974.	1.4	126
276	Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. Journal of Leukocyte Biology, 2008, 83, 589-601.	3.3	29
277	Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome. Blood, 2008, 112, 1038-1038.	1.4	2
278	SNP Array-Based Analysis of Chromosome 17 Reveals Biallelic TP53 Mutations Due to Uniparental Disomy 17p in Advanced MDS and AML with Cooperating Deletions of Chromosomes 5 and 7. Blood, 2008, 112, 2521-2521.	1.4	2
279	Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution. Blood, 2008, 112, 599-599.	1.4	3
280	FISH and SNP-Array Karyotyping Improve the Detection of Recurrent Chromosomal Defects Including Del(5q), Monosomy 7, Del(7q), Trisomy 8, and Del(20q) in Myelodysplastic Syndromes.. Blood, 2008, 112, 1483-1483.	1.4	0
281	Progressive Chromatin Repression and Promoter Methylation of a-catenin Correlates with AML Transformation in Patients with and without 5q Deletions.. Blood, 2008, 112, 3369-3369.	1.4	0
282	Investigations of Genetic Risk Factors in MDS and AML Using High- Density 6.0 Affymetrix Arrays. Blood, 2008, 112, 638-638.	1.4	1
283	BACH2 Directly Regulates Expression of Foxp3 in UCB CD4+ T-Cells. Blood, 2008, 112, 4760-4760.	1.4	0
284	Expression of MICA by Granulocytes in Neutropenia Due to Large Granular Lymphocyte Leukemia Points towards Cytotoxicity Exerted Via NKG2D on Clonal Cytotoxic T Cells.. Blood, 2008, 112, 1262-1262.	1.4	2
285	Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-Î³ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background. Blood, 2008, 112, 4116-4116.	1.4	0
286	SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS. Blood, 2008, 112, 639-639.	1.4	0
287	Alemtuzumab Shows Significant Efficacy in T-LGL Leukemia and Refractory Cases Are Due to GPI-Deficiency of LGL Clones.. Blood, 2008, 112, 2038-2038.	1.4	1
288	SNP-A Based Karyotyping Facilitates Improved Mapping of Deletions and Uniparental Disomy within the Long Arm of Chromosome 5 in Myeloid Disorders.. Blood, 2007, 110, 2435-2435.	1.4	1

#	Article	IF	Citations
289	Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients.. Blood, 2007, 110, 2450-2450.	1.4	2
290	SNP-Array Karyotyping Reveals the Presence of Previously Cryptic Clonal Chromosomal Aberrations Including Segmental UPD in Patients with Fanconi Anemia.. Blood, 2007, 110, 1678-1678.	1.4	0
291	SNP-A Karyotyping Demonstrates a High Incidence of Segmental Uniparental Disomy in Patients with CMML and Shows Impact of Newly Identified Chromosomal Aberrations on Clinical Course.. Blood, 2007, 110, 2428-2428.	1.4	0
292	SNP-Array-Based Karyotyping Has Impact on Cytogenetic Diagnosis and Prognosis of Non-Core Binding Factor Primary and Secondary AML.. Blood, 2007, 110, 597-597.	1.4	0
293	Can Genomic Copy Number Variants Be a Part of Complex Genetic Traits Predisposing to Marrow Failure?.. Blood, 2007, 110, 106-106.	1.4	0
294	SNP Arrays Facilitate Genotyping of Non-Synonymous SNP in MDS To Identify Disease Susceptibility Loci.. Blood, 2007, 110, 2421-2421.	1.4	0
295	Decreased Expression of Membrane-Bound Proteinase 3 by a GPI-Deficient Granulocytes May Contribute to Thrombophilic Propensity in PNH.. Blood, 2007, 110, 3673-3673.	1.4	3
296	SNP Array Karyotyping Improves Detection Rate of Clonal Chromosomal Abnormalities in Refractory Anemia with Ringed Sideroblasts.. Blood, 2007, 110, 4132-4132.	1.4	2
297	Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochemica Et Cytobiologica, 2007, 45, 5-14.	1.5	46
298	High Density SNP Arrays Reveal That Distinct Clonal Lesions Including Uniparental Disomy Can Be Detected in a Proportion of Patients with Aplastic Anemia with Normal Metaphase Cytogenetics.. Blood, 2006, 108, 125-125.	1.4	3
299	Identification of Chromosomal Abnormalities in Healthy Bone Marrow Using 250K SNP Arrays.. Blood, 2006, 108, 2076-2076.	1.4	1
300	Differential Expression of SLAM Family Receptor Markers in Normal Human Hematopoietic Stem Cells and Their Malignant Counterpart in MDS and AML.. Blood, 2006, 108, 1897-1897.	1.4	0
301	Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).. Blood, 2006, 108, 3012-3012.	1.4	9
302	A Decision Analysis To Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes.. Blood, 2005, 106, 2533-2533.	1.4	2
303	Phosphatidylinositol-3-Phosphate Kinase Pathway Activation Protects Leukemic Large Granular Lymphocytes from Undergoing Homeostatic Apoptosis.. Blood, 2005, 106, 739-739.	1.4	1
304	Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome.. Blood, 2005, 106, 369-369.	1.4	1
305	Molecular Identification of Alloreactive CTL Precursors in Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 597-597.	1.4	0
306	High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in MDS.. Blood, 2005, 106, 370-370.	1.4	0

#	Article	IF	Citations
307	Immunogenetic Factors Determining Evolution of T-Cell Large Granular Lymphocyte Leukemia and Associated Cytopenias.. Blood, 2005, 106, 2211-2211.	1.4	0
308	Evolution Of Clonal Cytogenetic Abnormalities in Aplastic Anemia. Leukemia and Lymphoma, 2004, 45, 433-440.	1.3	80
309	In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR Î²-CDR3 sequencing. Lancet, The, 2004, 364, 355-364.	13.7	223
310	Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. Blood, 2004, 104, 3782-3788.	1.4	41
311	Prospective Molecular Identification of Alloreactive CTL Clones in Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 4972-4972.	1.4	0
312	Differential Comparative Genomic Hybridization Analysis of Normal and Glycosyl Phosphatidyl Inositol Deficient Clones in Paroxysmal Noctorunal Hemoglobinuria.. Blood, 2004, 104, 2831-2831.	1.4	0
313	Pathologic Clonal CTLResponses - Non Random Nature of the TCR Restriction in LGL Leukemia.. Blood, 2004, 104, 3241-3241.	1.4	0
314	A Pilot Application of SELDI Serum Proteomics in Bone Marrow Failure Syndromes.. Blood, 2004, 104, 2822-2822.	1.4	0
315	KIR Gene Distribution in Hematologic Disorders.. Blood, 2004, 104, 1624-1624.	1.4	8
316	Polarized CTL Responses Detected in Patients with Autoimmune Neutropenia.. Blood, 2004, 104, 1459-1459.	1.4	8
317	In Search for the Specificity of Clonal CTL in T-LGL Leukemia - Generation of Soluble LGL-Derived T Cell Receptor.. Blood, 2004, 104, 4645-4645.	1.4	0
318	High-Resolution Genomic Scan for Cryptic Chromosomal Lesions in MDS and AML.. Blood, 2004, 104, 3427-3427.	1.4	0
319	Efficient Identification of T-Cell Clones Associated with Graft-Versus-Host Disease (GvHD) in Target Tissue for Subsequent Detection in Peripheral Blood.. Blood, 2004, 104, 2243-2243.	1.4	0
320	Hematopoietic stem cells in aplastic anemia. Archives of Medical Research, 2003, 34, 520-527.	3.3	37
321	Immune pathophysiology of aplastic anemia. International Journal of Hematology, 2002, 76, 207-214.	1.6	24
322	Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes â€œWhy? Why? Why?â€• Journal of Clinical Investigation, 2000, 106, 637-641.	8.2	82
323	The Pathophysiology of Acquired Aplastic Anemia. New England Journal of Medicine, 1997, 336, 1365-1372.	27.0	475